The life sciences sector is at a crossroads as the FDA updates quality management standards. AI is now expected, and the FDA’s January 2025 draft guidance outlines its evaluation and implementation. Successful adoption depends on three key questions.
Safe and Sane: Understanding the FDA’s Risk-Based Approach to AI
Related Posts
Supply Chains: Five-Fold Reconciliations
A robust supply chain should be successfully reconciled across five sources of information: Approved Vendors, Master Agreements, Transactions,…
Podcast: No More Command and Control!
Instead of telling people what to do, learn how to guide them to the best decisions. Read a…
Top 8 Use Cases of Generative AI in the Supply Chain Industry
Role of AI in Supply Chain 10 Use Cases of Generative AI in Supply Chain Opportunities and Challenges…
